Why Acutus Medical Is Turning Heads

Acutus Medical has landed on the radar of some of medtech's most reputable analysts, including Needham & Co.'s Mike Matson. MD+DI chatted with Acutus Medical President/CEO Vince Burgess to learn why the company is turning heads. AcQMap received a CE mark in May 2016 and subsequently launched in Europe. FDA cleared AcQMap in October 2017 and the Carlsbad, CA-based company launched in the United States in early 2018.  MD+DI: What, in your view, has put Acutus Medical on the radar this year? Burgess: We’re working in one of the most high profile spaces in all of medical devices, which is arrhythmia management. Of the markets over $1 billion in revenues in medical devices, only four or five markets of that size are growing over 10% per year and atrial fibrillation (Afib) management is one of those. So it’s a large market and it is also growing very quickly, which gets people’s attention. It’s growing in part because of demographics, atrial fibrillation is a disease of the aging and we have an aging population. There also has been an explosion of diagnostic products and capabilities that allow people to be much more aware of the presence of atrial fibrillation and connecting the dots between not feeling very well and their iWatch telling them they’...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news